Pay in 4 interest-free payments of $6.27 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
2021YFC2500600 and 2021YFC2500603)
Specificity Specifically binds with GSS , no obvious cross reaction with other analogues
March 2026: Novo Nordisk reported top-line REDEFINE-1 Phase 3 CagriSema data showing 22.7% mean body weight reduction at 52 weeks , demonstrating superiority over standalone semaglutide 2.4mg and confirming the semaglutide-plus-amylin combination as clinically competitive with tirzepatide
Purity & Documentation References [1]
US$ 23.92
US$ 26.96
US$ 29.84
US$ 23.50
